Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over

Arim Kwak; Jae Hyun Kim; Cheol Ung Choi; In Wha Kim; Jung Mi Oh; Kyungim Kim

doi:10.1007/s11096-019-00810-w

Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over

Arim Kwak, Jae Hyun Kim, Cheol Ung Choi, In Wha Kim, Jung Mi Oh, Kyungim Kim

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Background While there is clear evidence for the benefit of statins in the secondary prevention of cardiovascular and cerebrovascular events, there is a lack of research on the effects of statin regimens in older patients aged 75 years and over. Objectives To compare the effectiveness of statin regimens in the secondary prevention of ischemic cardiovascular and cerebrovascular events among patients aged 75 years and over. Setting Claims data from the South Korean National Health Insurance Database from 2006 to 2014. Methods This retrospective cohort study included patients aged 75–100 years with a prior history of cardiovascular or cerebrovascular disease who began statin therapy in 2009–2011. Propensity score matching and the Cox proportional hazards regression model were used to compare the effectiveness of the statin regimens in secondary prevention. Main outcome measure The hazard ratios for ischemic cardiovascular and cerebrovascular events and all-cause mortality. Results Neither high nor low-intensity statin therapy significantly differed from moderate-intensity statin therapy in preventing ischemic cardiovascular and cerebrovascular events or all-cause mortality. Of the moderate-intensity statin therapies, the use of 10 mg rosuvastatin was more strongly associated with a reduced risk of ischemic cardiovascular and cerebrovascular events than was 10 mg atorvastatin [HR 0.79 (95% CI 0.64–0.98), p = 0.029]. Subgroup analysis revealed that the protective effects of 10 mg rosuvastatin against ischemic cardiovascular and cerebrovascular events were more obvious for patients who were 75–79 years old, those who were statin-adherent, those who did not have diabetes mellitus at baseline, and those who were non-adherent to aspirin or antiplatelet drugs during the selection and follow-up periods. Conclusion The results of this study support the preferential prescription of moderate-intensity rosuvastatin over moderate-intensity atorvastatin for the secondary prevention of ischemic cardiovascular and cerebrovascular events in older patients aged ≥ 75 years.

Original language	English
Pages (from-to)	460-469
Number of pages	10
Journal	International Journal of Clinical Pharmacy
Volume	41
Issue number	2
DOIs	https://doi.org/10.1007/s11096-019-00810-w
Publication status	Published - 2019 Apr 15

Bibliographical note

Funding Information:
The authors would like to thank the South Korean National Health Insurance Service for the provision of the claims data from the South Korean National Health Information Database. This study was supported by the National Research Foundation, Korea (NRF-2017R1C1B5018232). The funding organization had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no conflicts of interest to declare.

Funding Information:
Funding This study was supported by the National Research Foundation, Korea (NRF-2017R1C1B5018232). The funding organization had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2019, Springer Nature Switzerland AG.

Keywords

Effectiveness
Ischemic event
Older people
Secondary prevention
South Korea
Statin

ASJC Scopus subject areas

Pharmacy
Toxicology
Pharmacology
Pharmaceutical Science
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11096-019-00810-w

Cite this

@article{766804f73f414d91bfaff849eb6efc52,

title = "Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over",

abstract = "Background While there is clear evidence for the benefit of statins in the secondary prevention of cardiovascular and cerebrovascular events, there is a lack of research on the effects of statin regimens in older patients aged 75 years and over. Objectives To compare the effectiveness of statin regimens in the secondary prevention of ischemic cardiovascular and cerebrovascular events among patients aged 75 years and over. Setting Claims data from the South Korean National Health Insurance Database from 2006 to 2014. Methods This retrospective cohort study included patients aged 75–100 years with a prior history of cardiovascular or cerebrovascular disease who began statin therapy in 2009–2011. Propensity score matching and the Cox proportional hazards regression model were used to compare the effectiveness of the statin regimens in secondary prevention. Main outcome measure The hazard ratios for ischemic cardiovascular and cerebrovascular events and all-cause mortality. Results Neither high nor low-intensity statin therapy significantly differed from moderate-intensity statin therapy in preventing ischemic cardiovascular and cerebrovascular events or all-cause mortality. Of the moderate-intensity statin therapies, the use of 10 mg rosuvastatin was more strongly associated with a reduced risk of ischemic cardiovascular and cerebrovascular events than was 10 mg atorvastatin [HR 0.79 (95% CI 0.64–0.98), p = 0.029]. Subgroup analysis revealed that the protective effects of 10 mg rosuvastatin against ischemic cardiovascular and cerebrovascular events were more obvious for patients who were 75–79 years old, those who were statin-adherent, those who did not have diabetes mellitus at baseline, and those who were non-adherent to aspirin or antiplatelet drugs during the selection and follow-up periods. Conclusion The results of this study support the preferential prescription of moderate-intensity rosuvastatin over moderate-intensity atorvastatin for the secondary prevention of ischemic cardiovascular and cerebrovascular events in older patients aged ≥ 75 years.",

keywords = "Effectiveness, Ischemic event, Older people, Secondary prevention, South Korea, Statin",

author = "Arim Kwak and Kim, {Jae Hyun} and Choi, {Cheol Ung} and Kim, {In Wha} and Oh, {Jung Mi} and Kyungim Kim",

note = "Funding Information: The authors would like to thank the South Korean National Health Insurance Service for the provision of the claims data from the South Korean National Health Information Database. This study was supported by the National Research Foundation, Korea (NRF-2017R1C1B5018232). The funding organization had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no conflicts of interest to declare. Funding Information: Funding This study was supported by the National Research Foundation, Korea (NRF-2017R1C1B5018232). The funding organization had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: {\textcopyright} 2019, Springer Nature Switzerland AG.",

year = "2019",

month = apr,

day = "15",

doi = "10.1007/s11096-019-00810-w",

language = "English",

volume = "41",

pages = "460--469",

journal = "International Journal of Clinical Pharmacy",

issn = "2210-7703",

publisher = "Springer Netherlands",

number = "2",

}

TY - JOUR

T1 - Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over

AU - Kwak, Arim

AU - Kim, Jae Hyun

AU - Choi, Cheol Ung

AU - Kim, In Wha

AU - Oh, Jung Mi

AU - Kim, Kyungim

N1 - Funding Information: The authors would like to thank the South Korean National Health Insurance Service for the provision of the claims data from the South Korean National Health Information Database. This study was supported by the National Research Foundation, Korea (NRF-2017R1C1B5018232). The funding organization had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no conflicts of interest to declare. Funding Information: Funding This study was supported by the National Research Foundation, Korea (NRF-2017R1C1B5018232). The funding organization had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: © 2019, Springer Nature Switzerland AG.

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Background While there is clear evidence for the benefit of statins in the secondary prevention of cardiovascular and cerebrovascular events, there is a lack of research on the effects of statin regimens in older patients aged 75 years and over. Objectives To compare the effectiveness of statin regimens in the secondary prevention of ischemic cardiovascular and cerebrovascular events among patients aged 75 years and over. Setting Claims data from the South Korean National Health Insurance Database from 2006 to 2014. Methods This retrospective cohort study included patients aged 75–100 years with a prior history of cardiovascular or cerebrovascular disease who began statin therapy in 2009–2011. Propensity score matching and the Cox proportional hazards regression model were used to compare the effectiveness of the statin regimens in secondary prevention. Main outcome measure The hazard ratios for ischemic cardiovascular and cerebrovascular events and all-cause mortality. Results Neither high nor low-intensity statin therapy significantly differed from moderate-intensity statin therapy in preventing ischemic cardiovascular and cerebrovascular events or all-cause mortality. Of the moderate-intensity statin therapies, the use of 10 mg rosuvastatin was more strongly associated with a reduced risk of ischemic cardiovascular and cerebrovascular events than was 10 mg atorvastatin [HR 0.79 (95% CI 0.64–0.98), p = 0.029]. Subgroup analysis revealed that the protective effects of 10 mg rosuvastatin against ischemic cardiovascular and cerebrovascular events were more obvious for patients who were 75–79 years old, those who were statin-adherent, those who did not have diabetes mellitus at baseline, and those who were non-adherent to aspirin or antiplatelet drugs during the selection and follow-up periods. Conclusion The results of this study support the preferential prescription of moderate-intensity rosuvastatin over moderate-intensity atorvastatin for the secondary prevention of ischemic cardiovascular and cerebrovascular events in older patients aged ≥ 75 years.

AB - Background While there is clear evidence for the benefit of statins in the secondary prevention of cardiovascular and cerebrovascular events, there is a lack of research on the effects of statin regimens in older patients aged 75 years and over. Objectives To compare the effectiveness of statin regimens in the secondary prevention of ischemic cardiovascular and cerebrovascular events among patients aged 75 years and over. Setting Claims data from the South Korean National Health Insurance Database from 2006 to 2014. Methods This retrospective cohort study included patients aged 75–100 years with a prior history of cardiovascular or cerebrovascular disease who began statin therapy in 2009–2011. Propensity score matching and the Cox proportional hazards regression model were used to compare the effectiveness of the statin regimens in secondary prevention. Main outcome measure The hazard ratios for ischemic cardiovascular and cerebrovascular events and all-cause mortality. Results Neither high nor low-intensity statin therapy significantly differed from moderate-intensity statin therapy in preventing ischemic cardiovascular and cerebrovascular events or all-cause mortality. Of the moderate-intensity statin therapies, the use of 10 mg rosuvastatin was more strongly associated with a reduced risk of ischemic cardiovascular and cerebrovascular events than was 10 mg atorvastatin [HR 0.79 (95% CI 0.64–0.98), p = 0.029]. Subgroup analysis revealed that the protective effects of 10 mg rosuvastatin against ischemic cardiovascular and cerebrovascular events were more obvious for patients who were 75–79 years old, those who were statin-adherent, those who did not have diabetes mellitus at baseline, and those who were non-adherent to aspirin or antiplatelet drugs during the selection and follow-up periods. Conclusion The results of this study support the preferential prescription of moderate-intensity rosuvastatin over moderate-intensity atorvastatin for the secondary prevention of ischemic cardiovascular and cerebrovascular events in older patients aged ≥ 75 years.

KW - Effectiveness

KW - Ischemic event

KW - Older people

KW - Secondary prevention

KW - South Korea

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85062938306&partnerID=8YFLogxK

U2 - 10.1007/s11096-019-00810-w

DO - 10.1007/s11096-019-00810-w

M3 - Article

C2 - 30864086

AN - SCOPUS:85062938306

SN - 2210-7703

VL - 41

SP - 460

EP - 469

JO - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

IS - 2

ER -